January 8th, 2020
•Here, we describe a simple and reproducible protocol of mouse model of infection to evaluate the attenuation of the genetically modified strains of Pseudomonas aeruginosa in comparison to the United States Food and Drug Administration (FDA)-approved Escherichia coli for commercial applications.
Vídeos Relacionados
Pseudomonas aeruginosa and Saccharomyces cerevisiae Biofilm in Flow Cells
Use of Artificial Sputum Medium to Test Antibiotic Efficacy Against Pseudomonas aeruginosa in Conditions More Relevant to the Cystic Fibrosis Lung
Long Term Chronic Pseudomonas aeruginosa Airway Infection in Mice
Pseudomonas aeruginosa Induced Lung Injury Model
Studying Microbial Communities In Vivo: A Model of Host-mediated Interaction Between Candida Albicans and Pseudomonas Aeruginosa in the Airways
A Simple and Efficient Approach to Construct Mutant Vaccinia Virus Vectors
Come to the Light Side: In Vivo Monitoring of Pseudomonas aeruginosa Biofilm Infections in Chronic Wounds in a Diabetic Hairless Murine Model
Replication of the Ordered, Nonredundant Library of Pseudomonas aeruginosa strain PA14 Transposon Insertion Mutants
Evaluating Virulence and Pathogenesis of Aeromonas Infection in a Caenorhabditis elegans Model
A Delayed Inoculation Model of Chronic Pseudomonas aeruginosa Wound Infection
SOBRE A JoVE
Copyright © 2024 MyJoVE Corporation. Todos os direitos reservados